2
VRTX icon

2Xideas’s Vertex Pharmaceuticals VRTX Stock Holding History

2Xideas’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-31,089
Closed -$12.6M – 54
2023
Q4 		$12.6M Sell
31,089
-3,870
-11% -$1.43M 1.36% 29
2023
Q3 		$12.2M Sell
34,959
-2,098
-6% -$734K 1.35% 21
2023
Q2 		$13M Buy
37,057
+576
+2% +$194K 1.25% 25
2023
Q1 		$11.5M Buy
36,481
+2,521
+7% +$756K 1.11% 38
2022
Q4 		$9.81M Buy
33,960
+1,776
+6% +$541K 1.04% 49
2022
Q3 		$9.32M Sell
32,184
-17,424
-35% -$5.01M 0.98% 27
2022
Q2 		$14M Sell
49,608
-22,157
-31% -$5.93M 1.28% 14
2022
Q1 		$18.7M Sell
71,765
-8,461
-11% -$2.01M 1.32% 13
2021
Q4 		$17.6M Buy
80,226
+23,363
+41% +$4.54M 1.06% 21
2021
Q3 		$10.3M Buy
56,863
+12,692
+29% +$2.48M 0.79% 61
2021
Q2 		$8.91M Buy
44,171
+8,097
+22% +$1.69M 0.8% 62
2021
Q1 		$7.75M Buy
36,074
+5,210
+17% +$1.14M 0.86% 59
2020
Q4 		$7.29M Buy
+30,864
New +$7.08M 0.91% 19

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

2Xideas's VRTX Position: Q1 2024 in Review

2Xideas sold out of Vertex Pharmaceuticals (VRTX) in Q1 2024, closing a stake of 31,089 shares — an estimated $12.6M sold.

2Xideas first reported a position in VRTX in Q4 2020 and held it in 13 quarters. The position peaked at $18.7M in Q1 2022. 1,493 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

  • 2Xideas reported no remaining Vertex Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • 2Xideas sold 31,089 Vertex Pharmaceuticals shares in Q1 2024, an estimated $12.6M.
  • 2Xideas first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 13 quarters.
  • 2Xideas's Vertex Pharmaceuticals position peaked at $18.7M in Q1 2022.
  • 1,493 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on 2Xideas's 13F filing for Q1 2024, filed 14 May 2024.